Rates of diagnosis and treatment are low, so there is a need for diagnostic tests and biomarkers for classification and ...

Anavex Life Sciences Corp (AVXL) reports a robust financial runway and unveils encouraging results for blarcamesine, despite ...

Eli Lilly & Biogen's Alzheimer's drugs may offer minimal impact despite aggressive marketing. Click here to get insights on ...

Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q2 2025 Earnings Conference Call. [Operator ...

When Eli Lilly (LLY) posted strong quarterly results, the stock fell from $750 to $625.65 by August 8. Shareholders fretted about clinical results from its next-generation obesity drug. Its 37.7% Y/Y ...

Eli Lilly reports strong Q2 2025 growth, driven by Mounjaro & Zepbound. Highlights include increased guidance, pipeline updates, and key clinical milestones.

Ever since Biogen and Eisai’s Aduhelm (aducanemab) was approved in 2021 as the first antibody to treat Alzheimer’s disease by ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Discover the latest non-invasive Alzheimer’s detection breakthroughs, from AI and heart rate tracking to digital twins and sensor tests.

Eli Lilly and Company LLY reported second-quarter 2025 adjusted earnings per share (“EPS”) of $6.31, which beat the Zacks ...